Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Voyager Therapeutics (VYGR) EBIT Margin (2016 - 2025)

Voyager Therapeutics' EBIT Margin history spans 11 years, with the latest figure at 501.07% for Q4 2025.

  • For Q4 2025, EBIT Margin rose 111112.0% year-over-year to 501.07%; the TTM value through Dec 2025 reached 62.09%, up 9386.0%, while the annual FY2025 figure was 62.09%, 4202.0% up from the prior year.
  • EBIT Margin for Q4 2025 was 501.07% at Voyager Therapeutics, up from 229.37% in the prior quarter.
  • Across five years, EBIT Margin topped out at 1584.71% in Q4 2022 and bottomed at 3244.68% in Q1 2022.
  • The 5-year median for EBIT Margin is 447.22% (2021), against an average of 593.17%.
  • The largest annual shift saw EBIT Margin plummeted -285106bps in 2022 before it surged 332634bps in 2023.
  • A 5-year view of EBIT Margin shows it stood at 20.31% in 2021, then skyrocketed by 7702bps to 1584.71% in 2022, then crashed by -103bps to 44.27% in 2023, then tumbled by -1278bps to 610.05% in 2024, then surged by 182bps to 501.07% in 2025.
  • Per Business Quant, the three most recent readings for VYGR's EBIT Margin are 501.07% (Q4 2025), 229.37% (Q3 2025), and 704.33% (Q2 2025).